53 results about "Vascular endothelial growth factor A" patented technology

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Cytoplasmic aspartate aminotransferase, soluble Tumor necrosis factor receptor superfamily member 5, soluble CD40 Ligand, soluble C-X-C Motif chemokine 16, S100-A12, Eotaxin, soluble E-selectin, Fibronectin, Granulocyte colony-stimulating factor, Granulocyte-macrophage colony-stimulating factor, Heparin-binding growth factor 2, soluble Hepatocyte growth factor receptor, Interleukin-1 receptor antagonist, Interleukin-1 beta, Interleukin-10, Interleukin-15, Interleukin-3, Myeloperoxidase, Nidogen-1, soluble Oxidized low-density lipoprotein receptor 1, Pappalysin-1, soluble P-selectin glycoprotein ligand 1, Antileukoproteinase, soluble Kit ligand, Tissue inhibitor of metalloproteinase 1, Tissue inhibitor of metalloproteinase 2, soluble Tumor necrosis factor, soluble Vascular cell adhesion molecule 1, and Vascular endothelial growth factor A as diagnostic and prognostic biomarkers in renal injuries.

Methods for accelerating and / or improving wound healing in a subject by administering vascular endothelial growth factor (VEGF) are provided.

The invention belongs to the field of biotechnology-monoclonal antibody. The present invention discloses a monoclonal antibody for antagonistic inhibition of combination of vascular endothelial cell growth factor (VEGF) and a receptor of the VEGF, and a hybridoma cell line secreting the monoclonal antibody, wherein the preservation number of the hybridoma cell line is CGMCC No.5889. The present invention further discloses a preparation method and a use of the monoclonal antibody, wherein the use comprises application of the monoclonal antibody in VEGF protein detection and application of the monoclonal antibody in preparation of a drug preparation for treatment of angiogenesis-related diseases.

The invention provides a carbohydrate composition with a wound healing promoting effect and application of the carbohydrate composition. The carbohydrate composition contains at least five types of carbohydrate including carboxymethyl chitosan, rhizoma bletillae polysaccharides, fucoidan from fucus vesiculosus, heparan sulfate, chondroitin sulfate, oligosaccharides of hyaluronan and gulose aldehyde acid oligosaccharides. The carbohydrate composition and the application have the advantages that VEGFA (vascular endothelial growth factor A), FGF2 (fibroblast growth factor 2) and VE-cadherin protein mRNA (messenger ribonucleic acid) expression can be obviously improved by the carbohydrate composition, VEGF (vascular endothelial growth factor) secretion and skin fibroblast (HSF) and human immortalized keratinocyte (HaCaT) proliferation can be obviously promoted by the carbohydrate composition, and the obvious wound healing promoting effect can be realized by the carbohydrate composition; raw materials required by the carbohydrate composition are easily available, composition methods for the carbohydrate composition are simple, the carbohydrate composition is low in cost, easy to industrialize and wide in application range, and the like.

The invention provides anti-aging agents, angiogenesis inhibitors and vascular endothelial growth factor (VEGF) expression inhibitors containing one or more galenicals selected from the group consisting of mukurossi peel extract, hazelnut extract, linden extract, coix extract, chlorella extract and tormentilla extract.

An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or assembly) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the VEGF-based agent is contained in a biocompatible coating that is applied to the microprojection member.

A precious metal plasma effect enhanced up-conversion fluorescence structure-based method for the hypersensitive detection of a vascular endothelial growth factor relates to the fields of nano-materials and analytical chemistry. A standard curve between the intensity of a fluorescence signal and the concentration of the vascular endothelial growth factor is established through synthesizing up-conversion nano-particles (NaYF4, Yb, Tm) with the particle size of 27.1 nm, synthesizing gold nano-particles with the particle size of 4.6 nm, modifying the up-conversion nano-particles, wrapping the gold nano-particles, carrying out single-strand DNA modification on the up-conversion nano-particles, carrying out single-strand DNA modification on the surface of the gold nano-particles, serially regulating a spacing between the particles, and carrying out enhanced regulation and intensity detection on the up-conversion fluorescence signal. Compared with traditional detection methods, the fluorescence enhanced signal-based method for detecting the vascular endothelial growth factor has the advantages of low background, high sensitivity, convenience, fastness and very good practical application prospect.

The invention discloses a latex-enhanced immunoturbidimetric kit for a vascular endothelial growth factor and an application of the kit. The kit comprises a reagent R1, a reagent R2 and a vascular endothelial growth factor calibrator, wherein the reagent R1 includes 3-(N-morpholinyl)propanesulfonic acid buffer, polyethylene glycol p-isooctyl phenyl ether, BSA, glycine, a surfactant and an antiseptic, and the reagent R2 comprises a phosphate buffer, latex microspheres coated with a vascular endothelial growth factor antibody, BSA, a surfactant, trehalose, mannitol, sucrose, PEG 6000, and an antiseptic. The kit allows a Fc segment of a VEFG antibody to be coupled with polystyrene latex particles through a directional coupling method. The coating effect is good, the antibody is not easy to beseparated from latex particles, and the utilization rate and detection sensitivity of the antibody are greatly improved.

The present invention relates to the field of pharmaceutical formulations of antibodies. Specifically, the present invention relates to a stable liquid antibody formulation and its pharmaceutical preparation and use. This invention is exemplified by an aqueous formulation of an anti-vascular endothelial growth factor (VEGF) antibody.

The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte / macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.

The invention discloses a novel medicinal application of fucoidan polysaccharide sulfate. The application refers to the application of fucoidan polysaccharide sulfate in the preparation of the following products: 1), a product for preventing and / or treating diabetic retinopathy, 2), a product for inhibiting retinal new capillaries, 3), a product for inhibiting VEGF (vascular endothelial growth factor) protein expression of retina tissue, and 4), a product for inhibiting HIF-1 alpha (hypoxia inducible factor-1 alpha)) protein expression of retina tissue. Preferably, the fucoidan polysaccharide sulfate is LMWF with the weight-average molecular weight of 3KD to 30KD. The pharmacodynamic experiment proves that the LMWF has a function in improving the retinopathy of STZ (streptozocin) induced diabetes mellitus mouse; under the function, the function of the retina capillaries is improved and the ischemia and anoxic state in retina are improved, therefore the down-regulation of expression of VEGF and HIF-1alpha are related; because the molecular weight of the LMWF is relatively small, the fucoidan polysaccharide sulfate can be adsorbed after being taken orally, the side effect is less, and therefore, the fucoidan polysaccharide sulfate has latent application significance in preventing and treating retinopathy.

The invention relates to a kit for predicting the curative effect of lucentis for treating age-related macular degeneration and belongs to the field of biotechnology. A method for predicting the curative effect of lucentis for treating the age-related macular degeneration comprises the following steps: extracting genome DNA of a host cell, measuring the genotype of a sixth intron rs142961510GA / -site of a VEGF-A (vascular endothelial growth factor-A) gene of a subject, and predicting the curative effect of the lucentis for treating age-related macular degeneration on the subject. By using the kit and the method provided by the invention, the susceptivity of the subject to the lucentis for treating the age-related macular degeneration can be predicted by measuring the polymorphism of an AMD related gene VEGF-A, and the method can be used for guiding individualized treatment of the age-related macular degeneration by using the lucentis.

The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte / macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.

The invention discloses an anti-human vascular endothelial growth factor (VEGFA) antibody, a preparation method and an application thereof. The heavy chain variable region of the VEGFA antibody comprises one or more of CDR1, CDR2 and CDR3, and an amino acid sequence and a nucleic acid sequence thereof are as described in the present invention respectively. the VEGFA antibody has high affinity andhigh biological activity, can be better combined with VEGF, and inhibit or block the binding of VEGF and VEGFR, so that a subsequent signal pathway and corresponding biological functions can be influenced, and the anti-human vascular endothelial growth factor can be well applied in anti-tumor, age-related macular degeneration, diabetic retinopathy, chronic eczema, rheumatoid arthritis and chronicinflammation.

The invention discloses application of RIPK4 as a target site in preparing urinary bladder carcinoma treating medicine. Researches show that RIPK4 in BUC is obviously improved, expression induction ofthe RIPK4 is excessive, and silent RIPK4 can inhibit in-vitro and in-vivo BUC invasion and metastasis. Therefore, the RIPK4 can serve as the target site to be applied to preparing urinary bladder carcinoma treating medicine. In addition, the condition RIPK4 up-regulation can cause vascular endothelial growth factor A (VEGF-A) level increasing is proved, so that the RIPK4 can be applied to preparing target negative regulation VEGF-A expression preparation. Meanwhile, VEGF-A can serve as a target site to be applied to preparing the urinary bladder carcinoma treating medicine.

A non-cell active derminal matrix used for skin transplanting contains the derminal matrix containing basically no cells and the cell factor chosen from fibroblast growth factor, vascular endothelial growth factor, platelet derived growth factor, transforming growth factor-alpha, or their mixture. Its advantages are high successful rate of skin transplantation and high transplant effect.

The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte / macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.

The present invention relates to a recombinant adenovirus capable of regulating angiogenesis, which comprises (a) an adenoviral UR (inverted terminal repeat) nucleotide sequence; and (b) a transcription regulatory sequence for a VEGF-A (vascular endothelial growth factor-A) gene comprising (i) a nucleotide sequence encoding a DNA binding domain comprising a zinc finger domain to bind to a site in a VEGF-A promoter sequence as set forth in nucleotides 1-2362 of SEQ ID NO:1, and (ii) a transcription activation domain or a transcription inhibitory domain linked to the nucleotide sequence encoding the DNA binding domain; and a pharmaceutical composition comprising the recombinant adenovirus.

The invention discloses a gene medicine for preventing and treating neovascular eye diseases. The invention relates to the technical field of gene medicines, in particular to a recombinant vector which comprises a PEDF or PEDF functional fragment gene and a shRNA fragment targeting human VEGFA (vascular endothelial growth factor A). The invention also provides application of the recombinant vector in preparation of medicines for preventing or treating angiogenesis-related eye diseases. The PEDF overexpression and VEGFA interference adeno-associated virus involved in the invention can interfere with the expression level of the VEGFA in vascular endothelial cells, effectively down-regulate the protein level of the VEGFA, further inhibit the proliferation and migration activity of the vascular endothelial cells, and inhibit the angiogenesis ability of the vascular endothelial cells, so that a new target and approach for the treatment of wet maculopathy is provided.

The invention discloses a monoclonal antibody, a composition taking same as an active ingredient, and application of the monoclonal antibody. The monoclonal antibody is a novel vascular endothelial growth factor A (VEGF-A) resistant human ScFv-Fc gene engineering antibody; the total molecular formula of the antibody is C2156H3272N561O681S12, and the molecular weight is 46KD; and the antibody is characterized in that: a full human antibody molecule specific to VEGF-A and capable of bonding with the VEGF-A in high affinity can be used for treating choroidal neovascularization (CNV) eye diseases. The monoclonal antibody can be widely applied and brings great social and economic benefits.

The present invention relates generally to methods of preventing or treating toxicities of the skin, hair, and / or nails, which are associated with administration of one or more vascular endothelial growth factor receptor inhibitors, with light-emitting diode photomodulation treatment, either alone or in combination with other agents.

The invention relates to a CTL (cytotoxic lymphocyte) epitope polypeptide of vascular endothelial growth factors and application of the CTL epitope polypeptide. Amino acid sequences of the CTL epitope polypeptide are shown as SEQ ID NO.3; a derivative sequence or a plurality of derivative sequences of amino acid is substituted, deleted, displaced, inserted and / or added to the CTL epitope polypeptide on the basis of the amino acid sequences show as the SEQ ID NO.3. The invention further provides vaccine. The vaccine comprises the CTL epitope polypeptide of the vascular endothelial growth factors and an adjuvant. The adjuvant is gp96 protein. The CTL epitope polypeptide, the application and the vaccine have the advantages that the adjuvant and the CTL epitope polypeptide of the vascular endothelial growth factors are matched with each other, accordingly, the immunity can be improved, tumor treatment effects can be obviously improved, and the like.

Vascular endothelial growth factor A (VEGFA) is a chemical signal produced by cells that stimulates the growth of new blood vessels, and overexpression of VEGFA can lead to undesirable physiological conditions. Through the identification of new siRNA and modifications that improve the silencing ability of these siRNA in vivo, therapeutic compositions and methods have been invented to address the problems associated with this overexpression.

The invention discloses a HER2 negative advanced gastric cancer patient first-line chemotherapy curative effect prediction model based on VEGFA and application thereof, the model comprises a line chart used for evaluating chemotherapy curative effect, scores corresponding to four indexes BMI, Diagnose Pattern, VEGFA and CA19-9 in the first row from the second row to the fifth row are added to obtain a total score of a sixth row of patients, and the total score of the sixth row of patients is calculated to obtain the first-line chemotherapy curative effect prediction model based on the HER2 negative advanced gastric cancer patient first-line chemotherapy curative effect prediction model based on the HER2 negative advanced gastric cancer patient first-line chemotherapy curative effect. And correspondingly projecting the total score of the patient in the sixth row to the seventh row to obtain the probability that the treatment of the patient is invalid. The curative effect prediction line diagram integrating serum VEGFA and common baseline characteristics is simple, clear, popular and easy to understand, and clinical doctors and patients can conveniently perform operation to predict the curative effect. Meanwhile, a satisfactory prediction result is displayed by a curative effect line diagram, clinical judgment and layering can be better guided, and certain help is provided for treatment of HER2 negative advanced gastric cancer patients in the future.